BTIG Maintains Buy on Castle Biosciences, Raises Price Target to $40
Portfolio Pulse from Benzinga Newsdesk
BTIG analyst Sung Ji Nam has maintained a Buy rating on Castle Biosciences and raised the price target from $35 to $40.
October 14, 2024 | 3:10 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BTIG analyst Sung Ji Nam has maintained a Buy rating on Castle Biosciences and increased the price target from $35 to $40, indicating a positive outlook.
The increase in the price target from $35 to $40 by BTIG suggests a positive outlook for Castle Biosciences, likely leading to a short-term increase in stock price as investors react to the analyst's confidence.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100